Loading…
Company secures up to $50.0 million in financing and reports study progress.
Quoin Pharmaceuticals Ltd. announced on 2026-08-28 Quoin Pharmaceuticals announced a private placement financing of up to $50.0 million and reported positive interim data from an ongoing Phase 2/3 study of QRX003 in Netherton Syndrome.
The announcement cited $50.0 million, $30.8 million, $19.2 million, $4.88 per ADS, $6.10 per ADS, 6,305,300 ADSs, 3,152,650 ADSs, 66.67%, -1.5 (SD 0.82), 50%, and 31%-87% improvement. Share consideration (payable in the issuer's shares): 6,305,300 ADSs.
Quoin Pharmaceuticals, Ltd. has a free float of 1,441,405 shares and 2,008,418 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.